Checkpoint Therapeutics’ (CKPT) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Checkpoint Therapeutics (NASDAQ:CKPT) in a research report sent to investors on Monday morning, Benzinga reports. HC Wainwright currently has a $20.00 price target on the stock.

Checkpoint Therapeutics Price Performance

Checkpoint Therapeutics stock opened at $2.34 on Monday. Checkpoint Therapeutics has a 1-year low of $1.30 and a 1-year high of $3.62. The company has a market cap of $105.35 million, a PE ratio of -0.84 and a beta of 1.29. The stock’s 50 day moving average price is $2.32 and its 200 day moving average price is $2.02.

Checkpoint Therapeutics (NASDAQ:CKPT) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.11. The business had revenue of $0.04 million during the quarter. On average, equities research analysts anticipate that Checkpoint Therapeutics will post -0.81 EPS for the current fiscal year.

Insider Activity at Checkpoint Therapeutics

In related news, CFO William Garrett Gray sold 13,038 shares of Checkpoint Therapeutics stock in a transaction that occurred on Wednesday, June 26th. The stock was sold at an average price of $2.06, for a total value of $26,858.28. Following the sale, the chief financial officer now directly owns 672,186 shares in the company, valued at $1,384,703.16. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other Checkpoint Therapeutics news, CFO William Garrett Gray sold 13,038 shares of the business’s stock in a transaction on Wednesday, June 26th. The stock was sold at an average price of $2.06, for a total transaction of $26,858.28. Following the sale, the chief financial officer now directly owns 672,186 shares in the company, valued at $1,384,703.16. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO James F. Oliviero III sold 24,610 shares of the business’s stock in a transaction on Wednesday, June 26th. The stock was sold at an average price of $2.05, for a total value of $50,450.50. Following the sale, the chief executive officer now owns 1,977,170 shares in the company, valued at $4,053,198.50. The disclosure for this sale can be found here. Company insiders own 2.10% of the company’s stock.

Institutional Trading of Checkpoint Therapeutics

A number of institutional investors have recently bought and sold shares of the company. Armistice Capital LLC boosted its position in Checkpoint Therapeutics by 17.5% during the fourth quarter. Armistice Capital LLC now owns 2,426,000 shares of the company’s stock worth $5,556,000 after purchasing an additional 362,000 shares in the last quarter. Vanguard Group Inc. boosted its position in Checkpoint Therapeutics by 67.4% during the first quarter. Vanguard Group Inc. now owns 917,894 shares of the company’s stock worth $1,882,000 after purchasing an additional 369,586 shares in the last quarter. B. Riley Wealth Advisors Inc. raised its holdings in shares of Checkpoint Therapeutics by 366.3% in the second quarter. B. Riley Wealth Advisors Inc. now owns 229,200 shares of the company’s stock worth $493,000 after acquiring an additional 180,050 shares during the last quarter. PVG Asset Management Corp acquired a new position in shares of Checkpoint Therapeutics in the second quarter worth $295,000. Finally, Choreo LLC raised its holdings in shares of Checkpoint Therapeutics by 12.2% in the second quarter. Choreo LLC now owns 65,002 shares of the company’s stock worth $133,000 after acquiring an additional 7,080 shares during the last quarter. 22.00% of the stock is currently owned by hedge funds and other institutional investors.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.